Skrabl-Baumgartner A, Erwa W, Muntean W, Jahnel J
a Department of Paediatrics and Adolescent Medicine , Medical University Graz , Austria.
b Institute of Medical and Chemical Laboratory Diagnostics , Medical University Graz , Austria.
Scand J Rheumatol. 2015;44(5):359-62. doi: 10.3109/03009742.2015.1022213. Epub 2015 May 14.
We aimed to determine how loss of response (LOR) to adalimumab (ADA) in juvenile idiopathic arthritis (JIA) may be related to anti-ADA antibodies (AAA).
AAA and ADA levels were measured in 23 consecutive patients with JIA responding significantly to treatment with ADA.
Six out of 23 (26%) patients developed AAA and had low ADA levels. Five out of six AAA-positive patients experienced LOR. In these patients use of concomitant methotrexate (MTX) was significantly lower.
The occurrence of AAA is a frequent event associated with LOR. Monitoring of AAA and serum ADA levels should be considered in JIA patients under ADA therapy.
我们旨在确定青少年特发性关节炎（JIA）患者对阿达木单抗（ADA）失去反应（LOR）与抗ADA抗体（AAA）之间的关系。
对23例连续使用ADA治疗有显著反应的JIA患者进行AAA和ADA水平检测。
23例患者中有6例（26%）出现AAA且ADA水平较低。6例AAA阳性患者中有5例出现LOR。这些患者同时使用甲氨蝶呤（MTX）的情况明显较少。
AAA的出现是与LOR相关的常见事件。接受ADA治疗的JIA患者应考虑监测AAA和血清ADA水平。
